 | | Vol. 14.35 – 8 September, 2022 |
| |
|
|
| Scientists investigated the effects of collagen on the characteristics of Wharton jelly (WJ)-MSCs associated with proliferation, surface markers, adhesion, migration, self-renewal, and differentiation capabilities through gene expression studies.
[Stem Cell International] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers investigated the role of human umbilical cord MSCs in managing erectile function in rat models of type 1 diabetes mellitus and type 2 diabetes mellitus and compared the effects of two different injection methods.
[Stem Cell Research & Therapy] |
|
|
|
| The authors performed a comparative evaluation of effects of normal-conditioned media (CM) and deferoxamine (DFS)-CM which were collected from normal and DFS preconditioned umbilical cord-derived MSCs on rat diabetic nephropathy model.
[Stem Cell Research & Therapy] |
|
|
|
| Scientists evaluated GMP manufactured clinical grade human Wharton’s Jelly MSCs in a mouse model of N-acetyl-para-aminophenol hepatotoxicity in comparison to human dermal fibroblasts.
[Archives of Toxicology] |
|
|
|
| The authors identified and investigated 35 small molecules that target hematopoietic stem cells quiescence factors.
[Journal of Cellular Biochemistry] |
|
|
|
| The effectiveness of tissue engineering materials combining porcine small intestine submucosa and umbilical cord (UC) MSCs on uterine injury in female rats after full-thickness uterine resection was evaluated as a basis for clinical treatment of the postoperative uterine injury.
[Tissue Engineering Part C-Methods] |
|
|
|
|
| Investigators discuss and review human umbilical cord blood mononuclear cells transplantation for perinatal brain injury.
[Stem Cell Research & Therapy] |
|
|
|
| The authors discuss the unwarranted decline in the use of umbilical cord blood as a source of donor hematopoietic stem cells for hematopoietic cell transplantation and the resulting important implications in addressing healthcare inequities.
[Current Opinion in Hematology] |
|
|
|
|
| Immutep Limited announced it has signed a Material Transfer Agreement with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland to enable an investigator-initiated open-label Phase II clinical trial.
[Immutep Limited] |
|
|
|
|
| January 22 – 25, 2022
Santa Fe, New Mexico, United States |
|
|
|
|
|
| | Karolinska Institutet – Flemingsberg, Sweden |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | Harvard Stem Cell Institute – Boston, Massachusetts, United States |
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
